Clinical trial
An Open-lable,Single-arm,Single-dose Escalation and Multiple-dose Expansion Clinical Study of Cell Therapy to Observe and Evaluate the Tolerance,Pharmacokinetic Characteristics,Safety and Efficacy of ScTIL210 in the Treatment of Melanoma
NCT04357509 is registered in ClinicalTrials.gov with Peking University Cancer Hospital & Institute as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- An Open-lable,Single-arm,Single-dose Escalation and Multiple-dose Expansion Clinical Study of Cell Therapy to Observe and Evaluate the Tolerance,Pharmacokinetic Characteristics,Safety and Efficacy of ScTIL210 in the Treatment of Melanoma
- Lead sponsor
- Peking University Cancer Hospital & Institute
- Phase
- Phase 1
- Overall status
- Unknown status
- Start date
- May 31, 2020
- Completion date
- December 31, 2021
- Enrollment
- 32 (estimated)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.